Trioday is a medication, containing three active ingredients, Tenofovir Disoproxil Fumarate, Lamivudine, and Efavirenz, and used to manage HIV in adult patients.
Tenofovir and Lamivudine are nucleotide reverse transcriptase inhibitors (NRTI), while Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI).
Tenofovir Disoproxil Fumarate first converts into tenofovir, an acyclic nucleotide analog of adenosine monophosphate, and next turns into the active metabolite, tenofovir diphosphate. Inside the cells, lamivudine metabolizes into 5-triphosphate (its active form). The major routes of Efavirenz metabolism constitute three hydroxylated metabolites: 8-hydroxy efavirenz, 8,14-dihydroxyefavirenz and 7-hydroxyefavirenz.
Trioday contains the recommended doses of its active ingredients: 300 mg of Tenofovir, 300 mg of Lamivudine, and 600 mg of Efavirenz.
Whereas both Tenofovir and Lamivudine can be taken with or without food, it is advised to take Efavirenz before going to bed and on an empty stomach to alleviate some the side effects associated with it. Therefore, Trioday is taken orally, before going to bed and on an empty stomach.
Please note that the therapy must be prescribed by a physician with the experience in HIV treatment.
The most common side effects of Trioday (with the frequency over 5% of the cases, ranging from mild to severe grades) include: asthenia, coughing, depression, diarrhea, dizziness, fatigue, general weakness, headache, insomnia, nasal symptoms, nausea, pain, skin rash.
Before starting the therapy, you must consult your physician. Trioday can be counter indicated in patients with the following conditions in their current or past medical history: age under 18; decreased kidney function; hypersensitivity, intolerance or life threatening allergic reactions to any components of the drug; peripheral neuropathy; simultaneous treatment with terfenadine, astemizole, cisapride, midazolam, and triazolam.
